Microbiologist and metabolomics specialist, Assistant Professor Mayo Clinic, passionate about microbiome therapeutics & personalized preventive health

Joined May 2009
A month ago, I shared how @GetTinyHealth started in my garage, with my mom hand-packing every kit. Today, the next chapter: we’ve raised a $33M Series B led by @BCapitalGroup, bringing our total funding to $46M. From newborns to centenarians, we’re building Tiny Health for you. ❤️
6
6
5
44
3,626
Ruben Mars retweeted
We don't make the results, we just report them! We're glad @_katetolo's doing so well. 🧬 And yes, we do have a test for that. tinyhealth.com/memberships/t…
Replying to @bryan_johnson
This is her vaginal microbiome report. 100/100 score. Top 1% of all vaginas. Her sample is dominated by the single most protective bacterial species a vagina can host (Lactobacillus crispatus). Only about 25-30% of reproductive age women globally are L. crispatus-dominant, and “dominant” usually means above 50%. Kate is at 98.7%. The lab found nothing bad to report. (no gardnerella, Candida, STIs, opportunistic pathogens, aerobic vaginitis markers, etc.) This is linked to lower risk of BV, UTIs, yeast infections, HPV persistence, HSV-2 and HIV acquisition, preterm birth, and improved IVF outcomes. A vaginal microbiome is downstream of everything: sleep, glucose control, stress, gut health, sexual health, immune function, what you eat, and what you put in it.
2
5
807
Ruben Mars retweeted
Top 1% of all vaginas tested! This is a real Tiny Health vaginal microbiome report. L. crispatus at 98.7% is linked to lower risk of BV, UTIs, yeast infections, and better fertility outcomes.
Replying to @bryan_johnson
This is her vaginal microbiome report. 100/100 score. Top 1% of all vaginas. Her sample is dominated by the single most protective bacterial species a vagina can host (Lactobacillus crispatus). Only about 25-30% of reproductive age women globally are L. crispatus-dominant, and “dominant” usually means above 50%. Kate is at 98.7%. The lab found nothing bad to report. (no gardnerella, Candida, STIs, opportunistic pathogens, aerobic vaginitis markers, etc.) This is linked to lower risk of BV, UTIs, yeast infections, HPV persistence, HSV-2 and HIV acquisition, preterm birth, and improved IVF outcomes. A vaginal microbiome is downstream of everything: sleep, glucose control, stress, gut health, sexual health, immune function, what you eat, and what you put in it.
2
2
8
2,280
Microbiome science is poised to redefine cancer care- but only if we move beyond correlations. The future lies in: 🎯Mechanistic precision 💻AI-guided interventions 🌎Real-world clinical validation to deliver more effective and tolerable cancer therapies. Check out more below from @KashyapPurna 's recent publication! ⬇️ rdcu.be/eXx4D #Mircobiome #GI #Excellence
2
10
802
New online! Harnessing the microbiome for cancer therapy nature.com/articles/s41579-0…
39
1
126
9,848
Using a reverse translation approach, @KashyapPurna and team identified a previously unrecognized role for the small intestinal microbiome and a specific microbial member in driving abdominal pain, a common and debilitating gastrointestinal symptom. Learn more about their findings in the publication below! @jclinicalinvest jci.org/articles/view/190638 #research #innovation
1
10
1
28
3,728
An exciting step for Tiny Health publishing their first randomized controlled trial on C-section infants: In response to the intervention program not only a dramatic shift in the gut microbiome was seen but even a reduced incidence of atopic conditions in the first year of life.
1
94
Today, I’m thrilled to announce our $8.5 million Series A round led by @SperoVentures, alongside partners @OverwaterVC, @nextcoastVP, @PetersonVenture, Modi Ventures, Tamarisc Ventures, @Cartancapital, and Taylor Sittler, Co-founder of @Color. axios.link/49VFat0
8
12
6
54
14,899
Our review now online @AGA_Gastro @rubenmars outlines current approaches & gaps and provides roadmap for accelerating translation of #gutmicrobiome science towards precision therapies in #FGID like #IBS. integrated #multiomics #AI longitudinal studies gastrojournal.org/article/S0… – at Minnesota, USA
5
20
4
83
Check out our paper in @iScience_CP on role of bacterially derived tryptamine in mucus release from goblet cells and sex-dependent attenuation of inflammatory response to DSS #IBD @MayoClinicCIM @MayoClinicGIHep @mfgrp @GutBugs2 @rubenmars @GFarrugiaMD sciencedirect.com/science/ar… – at Minnesota, USA
What is the best strategy for moving microbiome-based therapies for functional gastrointestinal disorders such IBS into the clinic? @rubenmars, Frith & @KashyapPurna updates major challenges in this field via @AGA_Gastro ow.ly/jEXR30rmhQQ
4
21
Multiple potential therapeutic targets for next-gen #probiotics – SCFA/tryptamine producing native/ engineered bacteria for IBS-C #syntheticbiology microbes that convert primary to secondary bile acid for IBS-D and hypoxanthine producing microbial consortia to treat #IBS symptoms
1
1
3
Check out our paper @CellCellPress bit.ly/3m5WDqt @rubenmars @KnightsDan integrating longitudinal host/#microbiome multi-omics in #IBS patients – shows purine starvation from host-microbial co-metabolism may underlie IBS. See video youtu.be/CxjRJuMVaOU @MayoClinic
9
39
6
114